[S(R)]-N-[(1R)-1-[2-(二苯基膦)苯基]乙基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[2-(二环己基膦)苯基](5,6,7,8-四氢-5,5,8,8-四甲基-2-萘基)甲基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[3,5-二叔丁基-4-甲氧基苯基][2-(二环己基膦)苯基]甲基]-2-叔丁基亚磺酰胺
[S(R)]-N-[(1S)-1-[2-(二环己基膦)苯基]乙基]-N-甲基-2-叔丁基亚磺酰胺
[S(R)]-N-[(1S)-1-[2-(9-蒽基)苯基]-2-(二苯基膦)乙基]-N-甲基-2-叔丁基亚磺酰胺
[S(R)]-N-[(S)-[2-(二苯基膦)苯基]苯基甲基]-N-甲基-2-叔丁基亚磺酰胺
溶解性 | DMSO ≥56mg/mL Water <1.2mg/mL Ethanol ≥35mg/mL |
存贮条件 | 室温 |
应用 | Iniparib (BSI-201) is an antineoplastic originally thought to be a poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor. Recent studies indicate Iniparib is not a PARP-1 inhibitor, and its mechanism of action is currently unknown. |
产品介绍 | Iniparib (BSI-201)是一种PARP1抑制剂,对三阴性乳腺癌(TNBC)有效。 |
备注 | BSI-201 (Iniparib, SAR240550) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3. |
生化机理 | BSI-201(Iniparib) is a potent PARP1 inhibitor with strong anti-neoplastic effect. |
别名 | 3-硝基-4-碘苯甲酰胺;BSI-201;Iniparib; NSC-746045; IND-71677; BSI 201; BSI201;4-Iodo-3-nitrobenzamide |